SPMs
| . | MPT-T . | mPR-R . | Total . |
|---|---|---|---|
| Treated patients | 148 | 150 | 298 |
| SPM events | 18 | 14 | 32 |
| IR/100 PY | 4.56 | 3.56 | 4.06 |
| Total | 12.2% | 9.3% | 10.7% |
| SPM excluding nonmelanoma skin and basal cell carcinoma | 14 | 8 | 22 |
| IR/100 PY | 3.47 | 2.01 | 2.74 |
| Total | 9.5% | 5.3% | 7.4% |
| . | MPT-T . | mPR-R . | Total . |
|---|---|---|---|
| Treated patients | 148 | 150 | 298 |
| SPM events | 18 | 14 | 32 |
| IR/100 PY | 4.56 | 3.56 | 4.06 |
| Total | 12.2% | 9.3% | 10.7% |
| SPM excluding nonmelanoma skin and basal cell carcinoma | 14 | 8 | 22 |
| IR/100 PY | 3.47 | 2.01 | 2.74 |
| Total | 9.5% | 5.3% | 7.4% |
IR, incidence rate; PY, person-years.